ClinicalTrials.gg
CompletedNCT01233258Leopold IIUpdated Nov 28, 2016Results posted

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

A Phase 3 interventional study of rFVIII (BAY81-8973) on demand and rFVIII (BAY81-8973) prophylaxis low-dose in Hemophilia A, sponsored by Bayer. Completed at 47 sites in 18 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
5th of 21
80 · median 50
Started
2011
with 1 other
Phase 3
4 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
3 of 21
Bayer

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 12th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to on-demand therapy with BAY81-8973 in patients with severe Hemophilia A. The hypothesis is that prophylaxis will result in fewer bleeds than on-demand treatment.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Haemophilia treatment
  • rFVIII
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 12 to 65 years
  • Severe hemophilia A
  • History of more than 150 exposure days (ED) with clotting factor concentrates
  • Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years
  • No current Factor VIII inhibitor or history of inhibitor
  • Willing to use electronic patient diary

Exclusion criteria

Exclusion Criteria:

  • Presence of another bleeding disease that is different from hemophilia A
  • Thrombocytopenia
  • Abnormal renal function
  • Presence of active liver disease
  • Known to FVIII
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Arm 1: rFVIII on demand first CS/EP then CS/ADJ

    Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.

    Biological: rFVIII (BAY81-8973) on demand

  • Experimental
    Arm 2: rFVIII on demand first CS/ADJ then CS/EP

    Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.

    Biological: rFVIII (BAY81-8973) on demand

  • Experimental
    Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ

    Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.

    Biological: rFVIII (BAY81-8973) prophylaxis low-dose

  • Experimental
    Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP

    Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.

    Biological: rFVIII (BAY81-8973) prophylaxis low-dose

  • Experimental
    Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ

    Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.

    Biological: rFVIII (BAY81-8973) prophylaxis high-dose

  • Experimental
    Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP

    Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.

    Biological: rFVIII (BAY81-8973) prophylaxis high-dose

Interventions

  • BiologicalrFVIII (BAY81-8973) on demand

    Drug pages: Antihemophilic factor, human recombinant · F8 protein, human

    Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization

  • BiologicalrFVIII (BAY81-8973) prophylaxis low-dose

    Drug pages: Antihemophilic factor, human recombinant · F8 protein, human

    Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.

  • BiologicalrFVIII (BAY81-8973) prophylaxis high-dose

    Drug pages: Antihemophilic factor, human recombinant · F8 protein, human

    Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.

06

What researchers measure

Primary outcomes

  1. Annualized Number of All Bleeds

    The annualized number of bleeds experienced by participants

    Time frame: Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)

Secondary outcomes

  1. Annualized Number of All Bleeds During CS/EP Period

    The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/EP

    Time frame: Up to 6 months (6 months on CS/EP potency assignment)

  2. Annualized Number of All Bleeds During CS/ADJ Period

    The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/ADJ

    Time frame: Up to 6 months (6 months on CS/ADJ potency assignment)

  3. Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)

    The percentage of bleeds per participant on on-demand treatment that stopped after two or fewer injections

    Time frame: Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)

Other outcomes

  1. Number of Bleeds During Treatment

    The number of bleeds experienced by each participant

    Time frame: 12 months

  2. Number of Participants With Inhibitory Antibody Formation

    A test to ensure that participants have not developed antibodies that will interfere with the action of rFVIII (BAY81-8973)

    Time frame: 3, 6, 9 and 12 months after baseline

07

Results

Posted Feb 11, 2014

Participant flow

Participants were recruited from specialized hemophilia treatment centers.

First Intervention (6 Months)
Participant flow — First Intervention (6 Months)
MilestoneOn Demand, BAY 81-8973 Potency First EP Then ADJOn Demand, BAY 81-8973 Potency First ADJ Then EPLow Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJLow Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EPHigh Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJHigh Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP
Started111014161616
Participants received treatment111013151615
Completed101013151615
Not completed101101
Withdrew: Withdrawal by subject000101
Withdrew: Protocol violation001000
Withdrew: Non-compliance with study medication100000
Washout (2-3 Days)
Participant flow — Washout (2-3 Days)
MilestoneOn Demand, BAY 81-8973 Potency First EP Then ADJOn Demand, BAY 81-8973 Potency First ADJ Then EPLow Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJLow Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EPHigh Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJHigh Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP
Started101013151615
Completed101013151615
Not completed000000
Second Intervention (6 Months)
Participant flow — Second Intervention (6 Months)
MilestoneOn Demand, BAY 81-8973 Potency First EP Then ADJOn Demand, BAY 81-8973 Potency First ADJ Then EPLow Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJLow Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EPHigh Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJHigh Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP
Started101013151615
Completed101013151615
Not completed000000

Outcome measures

PrimaryAnnualized Number of All Bleeds

The annualized number of bleeds experienced by participants

Time frame:
Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)
Reported as:
Mean · Bleeds per year per participant
Annualized Number of All Bleeds
Bleeds per year per participantrFVIII (BAY81-8973) on DemandrFVIII (BAY81-8973) Prophylaxis Treatment
Annualized Number of All Bleeds57.7 ± 24.64.9 ± 6.8
Statistical analysis
  • rFVIII (BAY81-8973) on Demand vs rFVIII (BAY81-8973) Prophylaxis Treatment · ANOVA · p = 0.0001 (No multiplicity adjustment as only 1 primary endpoint.)No adjustment, no transformation of data seemed to be necessary.
SecondaryAnnualized Number of All Bleeds During CS/EP Period

The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/EP

Time frame:
Up to 6 months (6 months on CS/EP potency assignment)
Reported as:
Mean · Bleeds per year per participant
Annualized Number of All Bleeds During CS/EP Period
Bleeds per year per participantrFVIII (BAY81-8973) on Demand Assayed by CS/EPrFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/EP
Annualized Number of All Bleeds During CS/EP Period57.6 ± 24.35.1 ± 8.0
Statistical analysis
  • rFVIII (BAY81-8973) on Demand Assayed by CS/EP vs rFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/EP · ANOVA · p = 0.0001 (No multiplicity adjustment as this is not primary endpoint.)No adjustment, no transformation of data seemed to be necessary.
SecondaryAnnualized Number of All Bleeds During CS/ADJ Period

The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/ADJ

Time frame:
Up to 6 months (6 months on CS/ADJ potency assignment)
Reported as:
Mean · Bleeds per year per participant
Annualized Number of All Bleeds During CS/ADJ Period
Bleeds per year per participantrFVIII (BAY81-8973) on Demand Assayed by CS/ADJrFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/ADJ
Annualized Number of All Bleeds During CS/ADJ Period59.7 ± 25.14.8 ± 6.8
Statistical analysis
  • rFVIII (BAY81-8973) on Demand Assayed by CS/ADJ vs rFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/ADJ · ANOVA · p = 0.0001No adjustment, no transformation of data seemed to be necessary.
SecondaryPercentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)

The percentage of bleeds per participant on on-demand treatment that stopped after two or fewer injections

Time frame:
Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)
Reported as:
Median · Percentage of bleeds
Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)
Percentage of bleedsrFVIII (BAY81-8973) on Demand Assayed by CS/EPrFVIII (BAY81-8973) on Demand Assayed by CS/ADJ
Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)96.8 (77.8 to 100.0)100.0 (65.7 to 100.0)
Statistical analysis
  • rFVIII (BAY81-8973) on Demand Assayed by CS/EP vs rFVIII (BAY81-8973) on Demand Assayed by CS/ADJ · Exact Permutation Test for paired sample · p = 0.0001 (No multiplicity adjustment as not primary endpoint.) · Median difference (net): -0.0001Confidence interval calculated with exact Hodges- Lehmann estimates for CS/EP minus CS/ADJ
Other pre-specifiedNumber of Bleeds During Treatment

The number of bleeds experienced by each participant

Time frame:
12 months
Reported as:
Median · Bleeds
Number of Bleeds During Treatment
BleedsrFVIII (BAY81-8973) on DemandrFVIII (BAY81-8973) Prophylaxis Low-doserFVIII (BAY81-8973) Prophylaxis High-dose
Number of Bleeds During Treatment60.0 (42.0 to 77.0)4.0 (0.0 to 8.0)2.0 (0.0 to 5.0)
Other pre-specifiedNumber of Participants With Inhibitory Antibody Formation

A test to ensure that participants have not developed antibodies that will interfere with the action of rFVIII (BAY81-8973)

Time frame:
3, 6, 9 and 12 months after baseline
Reported as:
Number · Participants
Number of Participants With Inhibitory Antibody Formation
ParticipantsrFVIII (BAY81-8973) on DemandrFVIII (BAY81-8973) Prophylaxis Low-doserFVIII (BAY81-8973) Prophylaxis High-dose
3 months after baseline000
6 months after baseline000
9 months after baseline000
12 months after baseline000

Adverse events

Collected over Treatment-emergent adverse event data reported here were collected from start of first treatment up to 12.5 months (end of observation period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rFVIII (BAY81-8973) Treatment—2/80 (2.5%)23/80 (28.8%)
Most frequent serious events
Most frequent serious events
EventrFVIII (BAY81-8973) Treatment
Head injuryInjury, poisoning and procedural complications1/80
AsthmaRespiratory, thoracic and mediastinal disorders1/80
Most frequent other events
Most frequent other events
EventrFVIII (BAY81-8973) Treatment
NasopharyngitisInfections and infestations13/80
Upper respiratory tract infectionInfections and infestations6/80
HeadacheNervous system disorders5/80
InfluenzaInfections and infestations4/80
InsomniaPsychiatric disorders4/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)rFVIII (BAY81-8973) on DemandrFVIII (BAY81-8973) Prophylaxis Low-doserFVIII (BAY81-8973) Prophylaxis High-doseTotal
Mean31.4 ± 10.928.8 ± 10.929.1 ± 11.529.6 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)rFVIII (BAY81-8973) on DemandrFVIII (BAY81-8973) Prophylaxis Low-doserFVIII (BAY81-8973) Prophylaxis High-doseTotal
Female0000
Male21283180
08

Study locations

47 sites
  • Dayton, Ohio 45404, United States
  • Houston, Texas 77030, United States
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1221ADC, Argentina
  • Rosario, Santa Fe S2000CKF, Argentina
  • Corrientes, W3410AVV, Argentina
  • Guangzhou, Guangdong 510515, China
  • Suzhou, Jiangsu 215006, China
  • Beijing, 100730, China
  • Shanghai, 200025, China
  • Tianjin, 300020, China
  • Bogotá, Distrito Capital de Bogotá, Colombia
  • Bucaramanga, Santander, Colombia
  • Olomouc, 77520, Czech Republic
  • Hyderabad, 500034, India
  • Jakarta, 10430, Indonesia
  • Nishinomiya, Hyogo 663-8501, Japan
  • Kashihara, Nara 634-8522, Japan
  • Shinjuku-ku, Tokyo 160-0023, Japan
  • Suginami, Tokyo 167-0035, Japan
  • Hiroshima, 734-8551, Japan
  • Guadalajara, Jalisco 44280, Mexico
  • San Luis Potosí, 78200, Mexico
  • Timisoara, Timis 300011, Romania
  • Baia Mare, 430031, Romania
  • Bucharest, 011026, Romania
  • Bucharest, 022328, Romania
  • Barnaul, 656050, Russian Federation
  • Khabarovsk, 680009, Russian Federation
  • St. Petersburg, 191186, Russian Federation
  • Yekaterinburg, 620149, Russian Federation
  • Beograd, 11000, Serbia
  • Kragujevac, 34000, Serbia
  • Nis, 18000, Serbia
  • Novi Sad, 21000, Serbia
  • Bratislava, 851 07, Slovakia
  • Johannesburg, Gauteng 2193, South Africa
  • Pretoria, Gauteng 0001, South Africa
  • Taichung, 40447, Taiwan
  • Taipei, 11217, Taiwan
  • Bangkok, 10400, Thailand
  • Bangkok, 10700, Thailand
  • Adana, 01330, Turkey
  • Antalya, 07059, Turkey
  • Izmir, 35-100, Turkey
  • Kiev, Ukraine
  • Lviv, 79044, Ukraine
  • Simferopol, 95023, Ukraine
09

References and documents

Publications

  • Kitchen S, Katterle Y, Beckmann H, Maas Enriquez M. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples. J Thromb Haemost. 2016 Jun;14(6):1192-9. doi: 10.1111/jth.13322. Epub 2016 May 3. PubMed 27002680 ↗
  • Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia. 2016 May;22(3):349-53. doi: 10.1111/hae.12839. Epub 2016 Mar 1. PubMed 26931631 ↗
  • Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015 Mar;13(3):360-9. doi: 10.1111/jth.12828. PubMed 25546368 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2010
First posted
Nov 3, 2010
Start
Jan 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Feb 11, 2014
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01233258
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 3, 2010
Start date
Jan 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Feb 11, 2014
Last update
Nov 28, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion